Innoviva Board Sends Letter to Shareholders
Company's Record of Creating Value and Proven Strategic Plan Supports a Vote by Shareholders "FOR" All of Innoviva's Highly Qualified Directors
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170403005524/en/
Dear Fellow Innoviva Shareholder:
The Annual Stockholder Meeting of
Innoviva's management team and Board have a strong track record of
creating value. We've delivered a 32% compound quarterly growth rate in
royalties earned in the last 10 reported quarters, significantly
improving our relationship with GlaxoSmithKline ("GSK"), resulting in
higher collaboration productivity, and maintaining our commitment to
returning capital to investors with more than
In addition, we believe that our current strategy of continuing to
invest in and improve the robust and collaborative relationship we have
with GSK is the best course to deliver significant value to Innoviva's
shareholders. Additional information regarding our collaboration with
GSK is enclosed with this letter and also is available by following this
link:
http://files.shareholder.com/downloads/THERA/4160966606x0x935648/B0196CD0-AFC7-4529-856D-6DF0F49BC16A/INVA_Shareholder_Letter_Attachment_4-3-17.pdf
Contrast Innoviva's proven strategy with the high-risk cost-cutting
that would be carried out by unqualified nominees proposed by a single
shareholder,
Mr. Denner's cost-cutting approach at Enzon resulted in catastrophic value destruction, including a stock price decline of 83% and a negative 52% total shareholder return during Mr. Denner's tenure as chairman. This was followed by Nasdaq's delisting of Enzon's stock.
Your highly qualified Board has provided skillful stewardship of
We thank you for your support and urge you to vote on the WHITE proxy card today.
Sincerely,
The Board of Directors of
Your Vote Is Important, No Matter How Many or How Few Shares You Own! |
Please vote today by telephone, via the |
By signing, dating and returning the enclosed WHITE proxy card. |
Simply follow the easy instructions on the WHITE proxy card. |
If you have questions about how to vote your shares, please contact: |
INNISFREE M&A INCORPORATED |
Shareholders |
(888) 750-5834 (TOLL-FREE from the |
or (412) 232-3651 (from other locations) |
Banks and Brokers May Call Collect: (212) 750-5833 |
REMEMBER: |
Please simply discard any Gold proxy card that you may receive from Sarissa. |
Returning a Gold proxy card - even if you "withhold" on Sarissa's nominees - |
will not help your Company, as it will revoke any vote you previously submitted |
on Innoviva's WHITE proxy card. |
Please visit http://investor.inva.com/proxy.cfm for more information. |
Forward-Looking Statements
This letter contains certain "forward-looking" statements as that term
is defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things, statements relating to Innoviva's
engagement with Sarissa.
About
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170403005524/en/
Investor Contact:
Eric d'Esparbes
Senior
Vice President and Chief Financial Officer
650-238-9640
investor.relations@inva.com
or
Media
Contacts:
212-371-5999 or 213-630-6550
pct@abmac.com
or ina@abmac.com
Source:
News Provided by Acquire Media